MYC and B-cell non-Hodgkin lymphoma: BCL-2 is detectable in approximately 50% of DLBCL and 75% of high-grade B-cell lymphomas, whose effect is to inhibit cell apoptosis and promote cell proliferation, which interacts with the action of C-MYC.